
Nyrada (ASX: NYR) shares have seen sharp volatility as traders react to its Xolatryp clinical progress and Phase IIa plans. Despite strong preclinical results and early trial safety data, the stock remains speculative, driven by momentum trading, retail interest, and upcoming biotech milestones.